Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells

被引:7
作者
Oswald, James T. [1 ]
Patel, Haritosh [1 ]
Khan, Daid [1 ]
Jeorje, Ninweh N. [1 ]
Golzar, Hossein [2 ,3 ]
Oswald, Erin L. [1 ]
Tang, Shirley [2 ,3 ]
机构
[1] Univ Waterloo, Sch Nanotechnol Engn, Waterloo, ON N2L 3G1, Canada
[2] Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada
[3] Univ Waterloo, Waterloo Inst Nanotechnol, Waterloo, ON N2L 3G1, Canada
关键词
Cancer Stem Cells (CSC); nanoparticles; targeted delivery; stem cell surface markers; liposomes; surface markers; ACUTE MYELOID-LEUKEMIA; GOLD NANOPARTICLES; IN-VITRO; PANCREATIC-CANCER; CARBON NANOTUBES; EMERGING ROLE; THERAPY; CD44; PROGRESSION; RESISTANCE;
D O I
10.2174/1381612826666200406084900
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The innate abilities of cancer stem cells (CSCs), such as multi-drug resistance, drug efflux, quiescence and ionizing radiation tolerance, protect them from most traditional chemotherapeutics. As a result, this small subpopulation of persistent cells leads to more aggressive and chemoresistant cancers, causing tumour relapse and metastasis. This subpopulation is differentiated from the bulk tumour population through a wide variety of surface markers expressed on the cell surface. Recent developments in nanomedicine and targeting delivery methods have given rise to new possibilities for specifically targeting these markers and preferentially eliminating CSCs. Herein, we first summarize the range of surface markers identifying CSC populations in a variety of cancers; then, we discuss recent attempts to actively target CSCs and their niches using liposomal, nanoparticle, carbon nanotube and viral formulations.
引用
收藏
页码:2057 / 2071
页数:15
相关论文
共 131 条
  • [1] AbuSamra DB, 2015, BLOOD, V126
  • [2] CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells
    Aigner, S
    Sthoeger, ZM
    Fogel, M
    Weber, E
    Zarn, J
    Ruppert, M
    Zeller, Y
    Vestweber, D
    Stahel, R
    Sammar, M
    Altevogt, P
    [J]. BLOOD, 1997, 89 (09) : 3385 - 3395
  • [3] Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells
    Aires, Antonio
    Ocampo, Sandra M.
    Simoes, Bruno M.
    Josefa Rodriguez, Maria
    Cadenas, Jael F.
    Couleaud, Pierre
    Spence, Katherine
    Latorre, Alfonso
    Miranda, Rodolfo
    Somoza, Alvaro
    Clarke, Robert B.
    Carrascosa, Jose L.
    Cortajarena, Aitziber L.
    [J]. NANOTECHNOLOGY, 2016, 27 (06)
  • [4] Rac1 Targeting Suppresses Human Non-Small Cell Lung Adenocarcinoma Cancer Stem Cell Activity
    Akunuru, Shailaja
    Palumbo, Joseph
    Zhai, Qihui James
    Zheng, Yi
    [J]. PLOS ONE, 2011, 6 (02):
  • [5] Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
    Al-Hussaini, Muneera
    Rettig, Michael P.
    Ritchey, Julie K.
    Karpova, Darja
    Uy, Geoffrey L.
    Eissenberg, Linda G.
    Gao, Feng
    Eades, William C.
    Bonvini, Ezio
    Chichili, Gurunadh R.
    Moore, Paul A.
    Johnson, Syd
    Collins, Lynne
    DiPersio, John F.
    [J]. BLOOD, 2016, 127 (01) : 122 - 131
  • [6] Targeting cancer stem cells in the clinic: Current status and perspectives
    Annett, Stephanie
    Robson, Tracy
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 187 : 13 - 30
  • [7] [Anonymous], P 4 IEEE INT NANOELE
  • [8] [Anonymous], CANCERS BASEL
  • [9] [Anonymous], DRUG RESISTANCE THEI
  • [10] [Anonymous], IMMUNOHISTOCHEM